biote Corp.

NASDAQ:BTMD

Medical - Care Facilities

Healthcare
$1.23 +0.22%

+$0.01 today

Market cap
$54.25M
Beta
1.66
P/E (TTM)
4.5
EPS (TTM)
$0.51
52W Low $1.27High $4.75

Volume 0.11M

Average 0.25M

BTMD Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

biote Corp.NASDAQ: BTMD

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses turns negative

Q1 FY2026 other income / expenses was -$1.17M, compared with $7M a year earlier. Trailing-twelve-month other income / expenses was -$8.51M.

Context

  • Other income / expenses amounted to 0.8% of revenue in FY2025, down 14.7 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$1.17M or moves back toward the trailing-twelve-month quarterly average of -$2.13M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.17M+27.7% QoQ
Last fiscal yearDec 2025
-$1.54M+95.0% YoY
LTMMar 2026
-$8.51M+13.5% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-116.7%——
1 year+95.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(1.54M) USD
Year-over-year change
+95.0%

Other Income / Expenses vs competitors

How BTMD compares with its peers on the latest reported figures

  • BTMD's LTM Mar 2026 other income / expenses of -$8.51M is the 9th highest of the 11 companies compared; the peer median is $1.02M.
  • Its year-over-year change of +13.5% is the 4th highest of 11, against a peer median of -39.3%.
  • Other income / expenses amounts to 4.5% of revenue for BTMD, versus a peer median of 43.3%.
BTMD Competitors Peer median
Other Income / Expenses for BTMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MCRBSeres Therapeutics, Inc.LTM Mar 2026$40.74M -24.4%—3552.1%
LUCDLucid Diagnostics Inc.LTM Mar 2026$4.26M +130.2%—82.9%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$2M -7.6%+38.7%1.7%
SPROSpero Therapeutics, Inc.LTM Mar 2026$1.99M -54.2%—3.6%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$1.34M -87.1%+1.6%—
JYNTThe Joint Corp.LTM Mar 2026$711.38K +65.0%—1.3%
ACTUActuate Therapeutics IncLTM Mar 2026$299.11K +119.3%+78.0%—
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$1.21M -112.8%——
BTMDbiote Corp.LTM Mar 2026-$8.51M +13.5%—4.5%
SCLXScilex Holding CompanyLTM Mar 2026-$116.93M -775.7%—345.3%
VORVor Biopharma Inc.LTM Mar 2026-$509.57M -14437.9%——
Peer median (excluding BTMD) $1.02M-39.3%+38.7%43.3%

Competitors are the stored peer set for BTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue139.4M164.96M185.36M197.19M192.22M
Cost of Revenue48.82M54.58M57.88M58.13M58.13M
Gross Profit90.58M110.38M127.48M139.06M134.09M
Gross Margin65.0%66.9%68.8%70.5%69.8%
Research & Development00000
Selling, General & Admin53.96M171.1M98.83M107.45M94.97M
Operating Expenses56.02M171.1M98.83M107.45M94.97M
Depreciation & Amortization1.4M2.2M794K3.57M3.67M
EBITDA35.98M7.96M39.54M15.59M53.12M
EBITDA Margin25.8%4.8%21.3%7.9%27.6%
Operating Income34.56M(60.72M)28.66M31.61M39.12M
Operating Margin24.8%-36.8%15.5%16.0%20.4%
Interest Income0000900K
Interest Expense1.67M4.05M6.36M11M11.86M
Other Income / Expenses(1.66M)62.43M(28.78M)(30.6M)(1.54M)
Income Before Tax32.91M1.71M(123K)1.02M37.58M
Pre-Tax Margin23.6%1.0%-0.1%0.5%19.6%
Income Tax Expense286K388K2.68M970K5.99M
Net Income32.62M(969K)3.32M3.16M27.05M
Net Margin23.4%-0.6%1.8%1.6%14.1%
EPS (Basic)(0.87)0.160.130.090.86
EPS (Diluted)(0.87)0.160.130.090.74
Weighted Avg Shares7.57M8.06M25.71M34.27M31.28M
Weighted Avg Shares (Diluted)7.57M8.06M25.71M34.27M36.67M

biote Corp.

NASDAQ:BTMD

Intrinsic Alpha fair value

Locked

Current Price

$1.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.